Edition:
India

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

18.10USD
24 Apr 2018
Change (% chg)

$-0.35 (-1.90%)
Prev Close
$18.45
Open
$18.45
Day's High
$18.45
Day's Low
$17.85
Volume
182,951
Avg. Vol
348,785
52-wk High
$24.45
52-wk Low
$5.15

Chart for

About

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $1,380.17
Shares Outstanding(Mil.): 59.75
Dividend: --
Yield (%): --

Financials

BRIEF-Dynavax Provides New Durability Of Response Data For SD-101 In Combination With Keytruda In Melanoma

* DYNAVAX PROVIDES NEW DURABILITY OF RESPONSE DATA FOR SD-101 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA AT THE 2018 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

17 Apr 2018

BRIEF-Dynavax Qtrly Loss Per Share $0.45

* DYNAVAX REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-Dynavax Secures $175 Million In Non-Dilutive Debt Financing

* DYNAVAX SECURES $175 MILLION IN NON-DILUTIVE DEBT FINANCING

20 Feb 2018

BRIEF-Dynavax Says Heplisav-B Available In U.S. For Prevention Of Hepatitis B In Adults

* DYNAVAX ANNOUNCES HEPLISAV-B™ IS NOW AVAILABLE IN THE UNITED STATES FOR THE PREVENTION OF HEPATITIS B IN ADULTS Source text for Eikon: Further company coverage:

08 Jan 2018

Dynavax's hepatitis B vaccine gets FDA nod on third try, shares up

Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug.

10 Nov 2017

BRIEF-Dynavax says FDA approves Heplisav-B for Hepatitis B prevention in adults

* Dynavax announces FDA approval of Heplisav-B for prevention of Hepatitis B in adults

10 Nov 2017

BRIEF-Dynavax reports Q3 loss per share $0.38

* Q3 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S

03 Nov 2017

Earnings vs. Estimates